VYNE Investor Relations Presentation
VYNE-Investor-Presentation
VYNE TherapeuticsRooted in Innovation
VYNE Therapeutics
VYNE-Investor-Presentation
KOL Event – Novel InhiBET BET Inhibitor Platform
BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced GB Patent No. 2621505 entitled “Pyrrolopyridone derivatives useful in the treatment of inflammatory disorders, immune disorders and cancer” has been granted by the United Kingdom’s Intellectual Property Office. This granted patent covers the compound in VYNE’s VYN202 program and has a 20-year term that will expire in June 2042. “The granting of this composition of matter patent is key to the development of VYN202, which…
BRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Subhashis Banerjee, M.D., as Senior Vice President of Clinical Development, effective as of July 8, 2024. Dr. Banerjee is a trained immunologist and rheumatologist with over 25 years of drug development experience at large pharmaceutical companies, including with the development of therapies for psoriasis and arthritic conditions. “We are pleased to welcome Dr. Banerjee to the VYNE team. His strong combination of…
Statement of changes in beneficial ownership of securities
Statement of changes in beneficial ownership of securities
Statement of changes in beneficial ownership of securities